ICAD - iCAD, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.9543
+0.0843 (+2.18%)
As of 12:16PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.8700
Open3.8000
Bid3.92 x 800
Ask3.99 x 900
Day's Range3.8000 - 4.0500
52 Week Range2.4200 - 4.6800
Volume14,058
Avg. Volume74,914
Market Cap66.32M
Beta (3Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of ICAD earnings conference call or presentation 13-Nov-18 9:30pm GMT

    Q3 2018 ICAD Inc Earnings Call

  • GlobeNewswire3 days ago

    iCAD Announces FDA Clearance of ProFound AI™ for Digital Breast Tomosynthesis

    High-performance, cancer detection technology built on artificial intelligence now available to healthcare facilities in the U.S. New U.S. clearance based on clinical results.

  • Zacks Small Cap Research13 days ago

    ICAD: Confident of FDA Approval of Tomo 2.0 (i.e. ProFound AI). New/Interim CEO Looks Like Perfect Fit

    Specifically, Detection product revenue missed our number by about 9% which was largely offset by slightly stronger than anticipated Therapy revenue (both product and services/supplies). Meanwhile, cash used in operating activities fell by $1.5M (or ~$600k ex-changes in working capital) over the same period. Cash used in operating activities was $859k less through the first nine months of 2018 as compared to the same period in 2017.

  • GlobeNewswire14 days ago

    iCAD Unveils ProFound AI™ for Digital Breast Tomosynthesis at RSNA 2018

    NASHUA, N.H. and CHICAGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- (Booth #3911 and #8161) – iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the global brand identity for its latest artificial intelligence software solution for digital breast tomosynthesis (DBT), ProFound AI™. This high-performance, deep-learning technology revolutionizes the way radiologists interpret and manage DBT data. Study results presented during an oral presentation at the Radiological Society of North America (RSNA) annual meeting at McCormick Place in Chicago showed that radiologists’ concurrent use of ProFound AI for DBT increased detection of breast cancer, while also decreasing false positives, unnecessary recalls and reading time.

  • How Financially Strong Is iCAD Inc (NASDAQ:ICAD)?
    Simply Wall St.25 days ago

    How Financially Strong Is iCAD Inc (NASDAQ:ICAD)?

    While small-cap stocks, such as iCAD Inc (NASDAQ:ICAD) with its market cap of US$47m, are popular for their explosive growth, investors should also be aware of their balance sheet to Read More...

  • Associated Press27 days ago

    Icad: 3Q Earnings Snapshot

    On a per-share basis, the Nashua, New Hampshire-based company said it had a loss of 8 cents. Losses, adjusted for severance costs and non-recurring costs, came to 6 cents per share. The imaging and early ...

  • GlobeNewswire27 days ago

    iCAD Reports Third Quarter 2018 Financial Results

    Company announces board and leadership changes Conference call today at 4:30 p.m. ET NASHUA, N.H., Nov. 13, 2018 -- iCAD, Inc. (NASDAQ: ICAD), a global medical.

  • GlobeNewswirelast month

    iCAD Announces Retirement of CEO, Ken Ferry

    NASHUA, N.H., Nov. 09, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Ken Ferry has retired from his position as Chief Executive Officer (CEO) and stepped down as a Director of the Company, effective immediately. Michael Klein, Chairman of iCAD’s Board, will serve as Executive Chairman and Interim CEO.

  • GlobeNewswirelast month

    iCAD to Report Third Quarter and Nine Months Ended September 30, 2018 Financial Results on Tuesday, November 13th

    NASHUA, N.H., Nov. 06, 2018 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.

  • GlobeNewswirelast month

    Navicent Health Adopts iCAD’s Breast Cancer Detection and Therapy Solutions to Enhance Patient Care

    Prominent medical center is first in the United States to expand breast health offerings with iCAD’s PowerLook Tomo Detection solution and Xoft System NASHUA, N.H., and MACON,.

  • GlobeNewswire2 months ago

    iCAD Announces New Clinical Data on the Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Demonstrating Positive Results

    NASHUA, N.H. and SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- (Booth #3457) – iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new clinical research demonstrating positive outcomes supporting the use of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer. Preliminary results demonstrated that IORT using the Xoft System is safe with excellent local control and cosmesis, and low morbidity.

  • GlobeNewswire2 months ago

    iCAD Announces Exceptional Study Results Demonstrating Significant Advantages of Revolutionary Artificial Intelligence Technology for Digital Breast Tomosynthesis

    NASHUA, N.H. and ATHENS, Greece, Oct. 11, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced outstanding clinical results of its new, leading-edge digital breast tomosynthesis (DBT) cancer detection software. The study demonstrated significant positive results for clinical performance and workflow efficiency.

  • GlobeNewswire2 months ago

    SUNY Upstate Medical University Selects iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment

    NASHUA, N.H. and SYRACUSE, N.Y., Oct. 09, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is now available at Upstate Medical University. Affiliated with the State University of New York, Upstate Cancer Center is the first facility in central New York State to offer treatment of early-stage breast cancer using intraoperative radiation therapy (IORT) with the advanced Xoft System.

  • GlobeNewswire2 months ago

    Sanford Health Announces Adoption of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment

    The new treatment of early-stage breast cancer using intraoperative radiation therapy (IORT) with the leading-edge Xoft System is a first for South Dakota and is offered through the Edith Sanford Breast Center. The medical facility is part of Sanford Health, the largest rural, not-for-profit healthcare system in the nation with 39 hospitals and 225 clinics serving 126 communities across nine states.

  • GlobeNewswire2 months ago

    Independent, Long-Term Study Highlights Effectiveness of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment

    NASHUA, N.H., Oct. 01, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term, independent study conducted with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT). With a mean follow-up of 55 months, outcomes published in The American Journal of Surgery showed that breast cancer recurrence rates of patients who were treated with IORT using the Xoft System and complied with adjuvant medical therapy were comparable to those seen in the cornerstone TARGIT-A study, which evaluated IORT using different technology.

  • iCAD Inc (NASDAQ:ICAD): Risks You Need To Consider Before Buying
    Simply Wall St.3 months ago

    iCAD Inc (NASDAQ:ICAD): Risks You Need To Consider Before Buying

    Anyone researching iCAD Inc (NASDAQ:ICAD) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...

  • Zacks Small Cap Research3 months ago

    ICAD: U.S. Tomo 2.0, Organic Therapy Growth and Leaner Ops Mean Profitability is Realistic

    Total revenue missed our number pretty handily, Detection revenue was well-below what we were looking for and tomo adoption does not appear to be as robust as hoped – and despite all that, Q2 2018 was one ICAD’s best quarters in a long time. Apples-to-apples total revenue was up 8% yoy, gross margins widened 730 bps and operating loss improved by $1.7M to just $939k – the lowest (i.e. As we hoped, shedding of the cash and resource-intensive therapy subscription business has resulted in a rapid improvement in margins and profitability.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ICAD earnings conference call or presentation 14-Aug-18 8:30pm GMT

    Q2 2018 ICAD Inc Earnings Call

  • Associated Press4 months ago

    Icad: 2Q Earnings Snapshot

    On a per-share basis, the Nashua, New Hampshire-based company said it had a loss of 6 cents. The imaging and early cancer detection company posted revenue of $6.2 million in the period. In the final minutes ...